Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $158.8 million.

  • Intellia Therapeutics' Long-Term Investments fell 4458.05% to $158.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.8 million, marking a year-over-year decrease of 4458.05%. This contributed to the annual value of $260.2 million for FY2024, which is 16056.94% up from last year.
  • Intellia Therapeutics' Long-Term Investments amounted to $158.8 million in Q3 2025, which was down 4458.05% from $170.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Long-Term Investments ranged from a high of $350.5 million in Q3 2021 and a low of $16.7 million during Q1 2021
  • Over the past 5 years, Intellia Therapeutics' median Long-Term Investments value was $162.1 million (recorded in 2024), while the average stood at $165.2 million.
  • In the last 5 years, Intellia Therapeutics' Long-Term Investments surged by 700532.86% in 2021 and then plummeted by 8855.7% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Long-Term Investments (Quarter) stood at $337.4 million in 2021, then plummeted by 79.45% to $69.3 million in 2022, then soared by 44.02% to $99.9 million in 2023, then soared by 160.57% to $260.2 million in 2024, then plummeted by 38.97% to $158.8 million in 2025.
  • Its Long-Term Investments was $158.8 million in Q3 2025, compared to $170.9 million in Q2 2025 and $203.4 million in Q1 2025.